Alunbrig 180 mg film-coated tablets

DRUG2 trials

Sponsors

Intergroupe Francophone De Cancerologie Thoracique, Prinses Maxima Centrum voor Kinderoncologie B.V.

Conditions

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other solid tumorsadvanced ALK-positive non-small cell lung cancer

Phase 1

A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors

RecruitingCTIS2024-513412-10-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

Start: 2022-05-11Target: 54Updated: 2025-12-09

Phase 2

IFCT-2101 MASTERPROTOCOL ALK A phase II randomized, open-labelled, multicenter study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer

Active, not recruitingCTIS2023-510387-13-00

Intergroupe Francophone De Cancerologie Thoraciqueadvanced ALK-positive non-small cell lung cancer

Start: 2022-05-18Target: 110Updated: 2025-02-11